Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Patrick Y. Wen, W. K. Alfred Yung, Ingo K. Mellinghoff, Shakti Ramkissoon, Brian Michael Alexander, Mikael L. Rinne, Howard Colman, Antonio Marcilio Padula Omuro, Lisa Marie DeAngelis, Mark R. Gilbert, John Frederick De Groot, Timothy Francis Cloughesy, Andrew S. Chi, Eudocia Quant Lee, Lakshmi Nayak, Tracy Batchelor, Susan Marina Chang, Michael Prados, David A. Reardon, Keith L. Ligon
Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, University of Utah, Huntsman Cancer Institute, University of California, Los Angeles, Harvard University, Massachusetts General Hospital, University of California, San Francisco, Boston Children's Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2586935306